Calcarea carbonica derivative complex (M8) as adjuvant treatment of inflammatory mammary carcinoma in a dog

Inflammatory mammary carcinoma (IMC) is locally aggressive, fast growing, a highly malignant tumor that affects humans and dogs. Affected dogs usually are presented with generalized edema, pain, erythema, and skin ulceration in mammary glands.

Surgery is not recommended, and effective treatment has not been established. Calcarea carbonica derivative complex (M8) is a complex high diluted homeopathic medicine. M8 demonstrated anticancer properties in a murine model, by improving innate immune response against tumor cells. At Veterinary Hospital of Federal University of Paraná, Brazil, it was used M8 in association with pyroxican (non-steroidal anti-inflammatory drug) to treat a dog with inflammatory mammary carcinoma.

A 7 years old, mixed breed intact female dog was presented with inflammation of mammary glands which was treated for mastitis (cephalexin and metergoline) without clinical improvement. Clinical examination revealed erythema, increased skin warmth, pain on palpation, and plaque involving the 4th and 5th left mammary glands. Abdominal ultrasound and serum biochemistry were unremarkable.

Cytological interpretation was a malignant epithelial neoplasm. Diagnosis of IMC was based on clinical signs and cytopathology. The dog was treated with oral (0.5 mL) and topical hydrogel M8 twice a day for 15 days, and pyroxican, 0.3mg/kg/24h. Clinical improvement was observed 7 days after starting treatment. Until present date dog has no clinical signs of IMC and does not show signs of disease progression.

Results: Clinical improvement was observed 7 days after starting treatment. Until present date dog has no clinical signs of IMC and does not show signs of disease progression.

Conclusion: The present report suggests that M8 associated with pyroxican contributes to improvement of IMC dog’s quality of life and survival rate.

Figure 1. Female dog with clinical and cytopathology signs of IMC. It presented a  mammary inflammation of 4th and 5th left mammary glands.
Figure 2. Sixty days after initial treatment there were no clinical signs of IMC